RightAnswer Knowledge Solutions Search Results for Azacitidine

New Search  |  Search Results (Azacitidine)  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Handling/Storage/Shipping/Waste Management
  • MSDS Documents
  • Personal Protection
  • Physical Hazards/Corrective Response Actions
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

HAZARDTEXT™ Documentshelp
MEDITEXT® Documentshelp

All Other Data Sources:

CCRIS Documentshelp
DART Documentshelp
• 2'-Deoxy-5-azacytidine and hind limb phocomelia in the CD-1 mouse.
• 5-Azacytidine-induced apoptosis in the central nervous system of developing rat fetuses.
• A bioassay that identifies postnatal functional deficits in mice prenatally exposed to xenobiotics.
Show More
ECOTOX Documentshelp
Fisher MSDShelp
GENE-TOX Documentshelp
HSDB® Data Bankhelp
LOLI® Listingshelp
NTP - Long-Term Studieshelp
REPROTOX® Documentshelp
RTECS® Registryhelp
Shepard's Cataloghelp
TERIS Documentshelp

ChemID External Links:

Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for Azacitidine:

Please note: this is an extract of information from a larger document. Full document and details are available by subscription.


  1. USES: Azacitidine is indicated for the treatment of various myelodysplastic syndrome subtypes including refractory anemia with or without ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
  1. PHARMACOLOGY: Appears to restore normal growth and differentiation of bone marrow cells by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. Hypomethylation may permit the normal functioning of genes that regulate differentiation and proliferation.
  1. EPIDEMIOLOGY: Overdoses are rare.
    1. COMMON: The most commonly occurring events (greater than 30%) following use include effects related to myelosuppression (ie, neutropenia, thrombocytopenia, anemia), fatigue, pyrexia, gastrointestinal symptoms (ie, nausea, vomiting, constipation or diarrhea), injection site reactions, petechiae, and hypokalemia.
    1. LESS FREQUENT: Other effects occurring less frequently include hypotension, myocarditis, mucositis, renal dysfunction, hepatic abnormalities, myalgias, rhabdomyolysis, headache, dyspnea, and coma.
    1. MILD TO MODERATE TOXICITY: Gastrointestinal effects (nausea, vomiting, diarrhea) occurred following administration of a single IV dose of approximately 290 mg/m(2), approximately 4 times the recommended starting dose.
    1. SEVERE TOXICITY: Severe toxicity following overdose has not been reported. It is anticipated that clinical effects will likely be an extension of adverse events (ie, myelosuppression, fatigue, nausea, vomiting, diarrhea).
© 2011-2021 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.